189 related articles for article (PubMed ID: 35039569)
1. Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.
Benoit A; Bou-Petit E; Chou H; Lu M; Guilbert C; Luo VM; Assouline S; Morin RD; Dmitrienko S; Estrada-Tejedor R; Johnson NA; Mann KK
Sci Rep; 2022 Jan; 12(1):779. PubMed ID: 35039569
[TBL] [Abstract][Full Text] [Related]
2. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
3. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
[TBL] [Abstract][Full Text] [Related]
4. Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway.
Lechuga CG; Simón-Carrasco L; Jacob HK; Drosten M
Methods Mol Biol; 2017; 1487():269-276. PubMed ID: 27924574
[TBL] [Abstract][Full Text] [Related]
5. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
6. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
7. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
8. Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival.
Bradley EW; Ruan MM; Vrable A; Oursler MJ
J Cell Biochem; 2008 Jul; 104(4):1439-51. PubMed ID: 18275061
[TBL] [Abstract][Full Text] [Related]
9. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
[TBL] [Abstract][Full Text] [Related]
10. Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells.
Kortum RL; Rouquette-Jazdanian AK; Samelson LE
Trends Immunol; 2013 Jun; 34(6):259-68. PubMed ID: 23506953
[TBL] [Abstract][Full Text] [Related]
11. HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.
Zhang X; Liu G; Ding L; Jiang T; Shao S; Gao Y; Lu Y
J Cell Biochem; 2018 Mar; 119(3):2864-2874. PubMed ID: 29073728
[TBL] [Abstract][Full Text] [Related]
12. Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways.
Peyssonnaux C; Provot S; Felder-Schmittbuhl MP; Calothy G; Eychène A
Mol Cell Biol; 2000 Oct; 20(19):7068-79. PubMed ID: 10982823
[TBL] [Abstract][Full Text] [Related]
13. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
14. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells.
Arai A; Aoki M; Weihua Y; Jin A; Miura O
Cell Signal; 2006 Dec; 18(12):2162-71. PubMed ID: 16781119
[TBL] [Abstract][Full Text] [Related]
15. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Shields JM; Thomas NE; Cregger M; Berger AJ; Leslie M; Torrice C; Hao H; Penland S; Arbiser J; Scott G; Zhou T; Bar-Eli M; Bear JE; Der CJ; Kaufmann WK; Rimm DL; Sharpless NE
Cancer Res; 2007 Feb; 67(4):1502-12. PubMed ID: 17308088
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
17. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
20. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
